Early and successful restoration of myocardial reperfusion following an ischemic event is the most effective strategy to reduce final infarct size and improve clinical outcome. However, revascularization per se may induce further myocardial damage by myocardial ischemia-reperfusion injury and worsen clinical outcome. Therefore, new therapeutic strategies are required to protect the myocardium against ischemia-reperfusion injury in patients with coronary artery disease. Remote ischemic conditioning (RIC) by brief nonlethal episodes of ischemia and reperfusion to an organ or tissue remote from the heart activates innate cardioprotective mechanisms. The discovery that RIC can be performed noninvasively using a blood pressure cuff on the upper arm to induce brief episodes of limb ischemia and reperfusion has facilitated the translation of RIC into the clinical arena. Whereas some trials have shown contradictory results, recently published proof-of-concept clinical studies have reported encouraging results with RIC. Large-scale multicenter clinical trials are needed to establish the role of RIC in the current clinical practice. At present, the use of RIC in acute coronary syndromes seems particularly attractive due to its potential in-ambulance application and apparent dramatic reduction in infarct size in the patients with the largest infarcts. Cardiac arrest and stroke represent ischemia-reperfusion disorders where RIC has further potential to improve outcome beyond rapid revascularization alone.